Company intelligence / Profile preview

Endogenex

Plymouth/Minneapolis, Minnesota, United Statesendogenex.com ↗

Ownership: Private
Development stage: Phase 3

Overview

The ReCET System has demonstrated substantial and durable reduction in insulin resistance and improvement in beta cell function for people with type 2 diabetes. In the REGENT‑1 Australia study, significant improvements were observed at both 12 weeks and sustained through to week 48. Procedural success was achieved in all cases with no serious device or procedure-related adverse events reported. The pivotal U.S./Australia trial of up to 350 patients is currently enrolling.

Therapeutic areas: Endocrinology
Modalities: DeviceNon-pharmacological therapy (endoscopic procedure using pulsed electric fields)
Industry: Therapeutic Medical Devices

Partnerships

Mayo Clinic (co-development/founding partner)

Beyond the preview

Go deeper on Endogenex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endogenex.

Explore the full profile